UNSPSC 51141584: Valpromide

This classification denotes an anticonvulsant and valproic acid analog with the molecular formula C8H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RUA6CWU76G, chemically known as valeramide, 2-propyl- but generally known as valpromide, which bears US NIH Compound Identifier 71113. European Medicines Agency schedules Valpromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00016MIG. World Health Organization schedules valpromide in its Anatomical Therapeutic Chemical (ATC) Classification.

VALPROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule valpromide under HS 29241900 and SITC 51471. As of Q4 2014, VALPROMIDE remains the US FDA Preferred Term for this commodity. SMILES: O=C(N)C(CCC)CCC.

UNSPSC 51141584 Valpromide, a Commodity code, encompasses pharmaceutical products and related health-supply systems that state and local governments procure to support community health initiatives, emergency response, and pharmacy benefit programs. The recent solicitations reveal a diverse portfolio: Seminole County, Florida is procuring naloxone and drug deactivation systems for community health delivery; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is sourcing generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local facilities in Minnesota and Oregon. Issuing bodies span county health departments, state health agencies, and cooperative purchasing consortia that aggregate demand across multiple jurisdictions and member states.

Geographic activity concentrates in the Upper Midwest and Southeast. The Minnesota MMCAP cooperative procurement (effective July 1, 2026, with proposals due March 26, 2026) covers Minnesota and Oregon participants; Seminole County, Florida released an IFB on June 30, 2026, with a response deadline of July 26, 2026 (note: the due date in the source is July 26, 2023, which appears inconsistent with the posted date of June 30, 2026, but the latter date governs); and the Texas HHS Commission issued an RFI on April 3, 2026, as exploratory market research prior to a formal RFP. The Minnesota and Texas opportunities signal state-level demand from larger health agencies managing pharmacy benefit spend, while the Seminole County IFB demonstrates county-level procurement of specialized health products with fixed quarterly delivery schedules and federal compliance requirements (FEMA funding, E-Verify, Clean Air Act and Federal Water Pollution Control Act adherence).